21st Jul 2020 15:51
Synairgen PLC - respiratory drug discovery firm spun-out of the University of Southampton - Clarifies that SNG001 trial in hospitalised Covid-19 patients is a phase II trial. Adds that it is working with regulators to progress the potential Covid-19 treatment "as rapidly as possible". "As with any drug undergoing clinical trials, Synairgen will require regulatory approval before SNG001 can be marketed on a commercial basis."
Current stock price: 187.20 pence
Year-to-date change: up sharply from 5.88p on December 31
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Synairgen